Share this Page:
Metastasectomy is surgery to remove one or more tumours that have formed from cells that have spread from the primary tumour (metastases).
This study looked at the effect of metastsectomy on the survival of patients with kidney cancer that had spread (metastatic). In total, 431 patients were included. Fifty-nine (59) patients had favourable-risk disease, 274 intermediate-risk disease, and 98 high-risk disease. More patients had a metastasectomy in the favourable-risk group (37%) than in the intermediate- and high-risk groups (24% and 16% respectively).
For people with favourable-risk kidney cancer, those who had metastasectomy had a longer average overall survival time than those who did not (92.7 months compared to 25.8 months). The same was true for patients with intermediate-risk kidney cancer (51.8 months compared to 26.4 months), but not those in the high-risk group.
Metastasectomy may provide a survival benefit in select patients with kidney cancer that has spread, especially for those with favourable- or intermediate-risk disease.
